Studies of rituximab maintenance therapy in indolent lymphomas
| Trial . | Disease setting . | Diseases included . | Previous therapy . |
|---|---|---|---|
| ECOG55 | First line | Follicular, small lymphocytic | CVP |
| SAKK56 | First line, relapsed/refractory | Follicular, mantle cell | Rituximab |
| EORTC57 | Relapsed/refractory | Follicular | CHOP vs R-CHOP |
| GLSG58 | Relapsed/refractory | Follicular, mantle cell | FCM vs R-FCM |
| LYM-559 | Relapsed/refractory | Follicular, small lymphocytic | Rituximab |
| Trial . | Disease setting . | Diseases included . | Previous therapy . |
|---|---|---|---|
| ECOG55 | First line | Follicular, small lymphocytic | CVP |
| SAKK56 | First line, relapsed/refractory | Follicular, mantle cell | Rituximab |
| EORTC57 | Relapsed/refractory | Follicular | CHOP vs R-CHOP |
| GLSG58 | Relapsed/refractory | Follicular, mantle cell | FCM vs R-FCM |
| LYM-559 | Relapsed/refractory | Follicular, small lymphocytic | Rituximab |